The Global Photonics Community Converges in San Francisco as More Than 23,000 Register for Photonics West 2026
3.2.2026 22:14:00 CET | Business Wire | Press Release
SPIE, the international society for optics and photonics, brought the global optics and photonics community to San Francisco, California, for another successful and enlivening Photonics West. With more than 23,000 registrants, the annual conference and exhibition connected attendees from 40 countries, showcasing the transnational and collaborative spirit of the interdisciplinary industry. The dynamic event ran from 17 to 22 January, with 4,200 technical presentations across 100 conferences, 4 stages of industry-focused panels and presentations, 49 courses, and approximately 1,600 exhibitors in the five expos: Photonics West, BiOS, Quantum West, AR | VR | MR, plus, in its inaugural year, Vision Tech.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203925940/en/
Attendees of the 2026 SPIE Photonics West fill the Moscone Center, where nearly 1,600 exhibitors showcased their products.
With an emphasis on the application of advanced vision technologies, the inclusion of Vision Tech Expo brought a new audience this year, and the complementary technical program highlighted how photonics inventions are enabling advancements in the manufacturing, automotive, life sciences, agriculture, and robotics sectors. Similarly, the AR | VR | MR and Quantum West expo and technical programs highlighted the role photonics is having on the next generation of technologies coming to market.
Providing economic data that added context and support to the positivity experienced on the show floors, SPIE also released its annual Optics and Global Industry Report during the SPIE Global Business Forum on 19 January. To an audience of photonics executives and leaders, the society reported that global annual revenue from production of optics and photonics core components in 2024 increased 10% from 2023, reaching $381 billion.
“Attending Photonics West every year is the best way to see and experience the size and interdisciplinary nature of our industry,” said Director of Technology Outreach, Amy Hanlon, who presented the report. “Coming here and walking the show floors, I’m always impressed by the number of people, the ingenuity of the companies, and the ever-evolving array of products they create to help address global challenges and move technology forward. You pair the experience this week with the data from the Global Industry Report, and it’s clear that optics and photonics are vital technologies enabling economic growth, solving real-world problems, and bringing innovations to market.”
Beyond the tradeshows and industry programs, SPIE Photonics West included over 25 plenary presentations showcasing the latest groundbreaking research from around the globe, as well as thousands of thought-provoking presentations from academia and industry covering every aspect of optics and photonics in the BiOS, LASE, OPTO, Quantum West, AR|VR|MR, and Vision Tech conferences. The most elegant event of the show, the Prism Awards, honored winners in nine categories, recognizing those leading the charge in innovative optics and photonics products. Perhaps with a glimpse into future Prism Award winners, the 16th annual Startup Challenge gave seven finalists the chance to pitch their innovative, investment-ready optics and photonics technologies to a panel of six industry judges, with Coalesenz Inc. announced as the winner. For first-time and veteran attendees alike, Photonics West is the premier event for lasers, biomedical optics, optoelectronics, and technologies supporting biophotonic, quantum, and vision applications.
Steve Sokach, Director of Sales for SCHOTT North America said, “We’ve been involved [with Photonics West] from the beginning.” When asked what keeps SCHOTT coming back each year, Sokach replied, “These opportunities, seeing how the market has developed, seeing what’s new in the industry, seeing the evolution of products. Just the ability to network with so many customers at one time. Also to get a gauge as to what’s new and emerging, where we need to play.” He added, “This is great market intelligence for us. To give a simple indication, fifteen years ago there was no AR / VR hall, and now [SCHOTT] has a prominent display in the AR | VR | MR Exhibition because of some of the things we have learned by coming to exhibitions like [Photonics West].”
Brooke Nagle, Senior Manager of Marketing and Communications with Optikos, was attending Photonics West for the first time. “Everyone has been incredibly welcoming, and everything is very well-labeled, which I appreciate.” When asked about the connections she has made during her time exhibiting, she said, “There are so many people walking around, simply being curious, and I think the curiosity is something that sets this show apart. [Photonics West] feels like less of a sales push and more of a conversation.”
“We always leave [Photonics West] with focus and new ideas,” Stacie Foster, Marketing Manager with TOPTICA Photonics and many-year attendee of the show. “SPIE does it the best.”
"One of the most inspiring elements of Photonics West is seeing thousands of optics and photonics professionals of all levels engaging, connecting, and sharing ideas with each other," said SPIE CEO Kent Rochford. "This world-class event has become paramount to the industry, and we are proud to bring the global community together each year to learn from each other, understand trends, and collaboratively plan ahead. I am already looking forward to the conversations and innovation at Photonics West 2027 next January."
View highlights from the week, including links to the Show Dailies and coverage in the press. This page will continue to be updated with new photos and articles as they are released.
SPIE Photonics West 2027 will take place 30 January – 4 February at the Moscone Center in San Francisco. The call for papers for the 2027 event will open in Spring of 2026.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, we have invested more than $26 million in the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. spie.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20260203925940/en/
Contacts
Lindsey McGuirk
Public Relations Manager
lindseym@spie.org
+1 360 685 5443
@spie.org -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbsky.app%2Fpro
file%2Fspie.org&esheet=54413800&newsitemid=20260203925940&lan=en-US&anchor=%40sp
ie.org&index=10&md5=8adb73e11209385d9e2ec2b817ee213e
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom